CAVALLETTO, LUISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.588
AS - Asia 4.642
EU - Europa 2.327
AF - Africa 805
SA - Sud America 790
OC - Oceania 82
Continente sconosciuto - Info sul continente non disponibili 66
Totale 16.300
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.119
SG - Singapore 1.557
CN - Cina 763
VN - Vietnam 650
IT - Italia 486
HK - Hong Kong 481
BR - Brasile 465
DE - Germania 272
FI - Finlandia 231
FR - Francia 185
BD - Bangladesh 131
IN - India 128
SE - Svezia 127
PL - Polonia 117
GB - Regno Unito 100
UA - Ucraina 93
IQ - Iraq 77
AR - Argentina 72
TR - Turchia 70
RU - Federazione Russa 62
CA - Canada 53
JP - Giappone 51
ID - Indonesia 50
NL - Olanda 50
PH - Filippine 49
SA - Arabia Saudita 48
CO - Colombia 46
MX - Messico 45
ZA - Sudafrica 42
PK - Pakistan 41
ES - Italia 38
AL - Albania 36
EC - Ecuador 35
IE - Irlanda 34
UZ - Uzbekistan 33
ET - Etiopia 32
KE - Kenya 32
MA - Marocco 32
CI - Costa d'Avorio 31
CL - Cile 31
PS - Palestinian Territory 31
SI - Slovenia 31
LC - Santa Lucia 30
NP - Nepal 30
TH - Thailandia 30
JM - Giamaica 29
LB - Libano 29
PE - Perù 29
NI - Nicaragua 28
PA - Panama 28
GT - Guatemala 27
MY - Malesia 27
EG - Egitto 26
MN - Mongolia 26
NO - Norvegia 26
RO - Romania 26
AO - Angola 25
HN - Honduras 25
KG - Kirghizistan 25
MZ - Mozambico 25
TN - Tunisia 25
AT - Austria 24
BY - Bielorussia 24
CR - Costa Rica 24
DK - Danimarca 24
PY - Paraguay 24
GR - Grecia 23
KH - Cambogia 23
PT - Portogallo 23
RS - Serbia 23
VE - Venezuela 23
AE - Emirati Arabi Uniti 22
BG - Bulgaria 22
BO - Bolivia 22
JO - Giordania 22
MG - Madagascar 22
TT - Trinidad e Tobago 22
UY - Uruguay 22
ZM - Zambia 22
CW - ???statistics.table.value.countryCode.CW??? 21
HU - Ungheria 21
LV - Lettonia 21
SD - Sudan 21
UG - Uganda 21
BW - Botswana 20
BZ - Belize 20
CV - Capo Verde 20
DZ - Algeria 20
GM - Gambi 20
GN - Guinea 20
KR - Corea 20
KZ - Kazakistan 20
MD - Moldavia 20
PR - Porto Rico 20
YE - Yemen 20
ZW - Zimbabwe 20
AZ - Azerbaigian 19
BE - Belgio 19
CG - Congo 19
CY - Cipro 19
Totale 15.405
Salva come PNG Salva come JPEG
Città #
Singapore 976
San Jose 885
Ashburn 694
Fairfield 644
Jacksonville 451
Hong Kong 427
Houston 423
Woodbridge 384
Chandler 379
Wilmington 285
Cambridge 254
Ann Arbor 213
Seattle 210
Ho Chi Minh City 202
Boardman 162
Hanoi 158
Princeton 152
Los Angeles 130
Santa Clara 129
Beijing 105
Helsinki 102
Lauterbourg 101
Munich 101
Bytom 95
Medford 83
San Diego 76
Nanjing 74
New York 70
Des Moines 49
Milan 43
Guangzhou 39
São Paulo 39
Buffalo 34
Roxbury 34
Dallas 33
Rome 33
Haiphong 32
Baghdad 30
Castries 30
Da Nang 30
Dublin 30
Chicago 29
Abidjan 28
Addis Ababa 27
Managua 27
Orem 27
Panama City 27
Tashkent 27
Nanchang 26
Ulan Bator 25
Council Bluffs 24
Hefei 24
Nairobi 24
Turku 24
Hebei 23
Naples 23
Tokyo 23
Redondo Beach 22
Tianjin 22
Bishkek 21
London 21
Lusaka 21
San José 21
Shenyang 21
Amman 20
Kampala 20
Phnom Penh 20
Tirana 20
Baku 19
Conakry 19
Luanda 19
Montevideo 19
Padova 19
Riyadh 19
Stockholm 19
Willemstad 19
Antananarivo 18
Brooklyn 18
Harare 18
Jeddah 18
Johannesburg 18
Minsk 18
Bamako 17
Chennai 17
Guatemala City 17
Khartoum 17
Lima 17
Maputo 17
Noumea 17
Praia 17
Riga 17
Shanghai 17
Bangkok 16
Changsha 16
Frankfurt am Main 16
Hải Dương 16
Jinan 16
Libreville 16
Vienna 16
Bogotá 15
Totale 9.615
Salva come PNG Salva come JPEG
Nome #
LA CURA DEL PAZIENTE CON EPATITE C: dall'epidemiologia alla buona pratica clinica attraverso metodologie sperimentali e di laboratorio. 481
Newly diagnosed Hepatocellular Carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study 317
Prognostic value of liver and spleen stiffness in patients with fontan associated liver disease (Fald): A case series with histopathologic comparison 285
Peripheral neurotoxicity of pegylated interferon alpha: a prospective study in patients with HCV. 258
Cognitive effects of long-term interferon treatment for chronic viral hepatitis 237
Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma 227
SERPINB3 expression on B-cell surface in autoimmune diseases and hepatitis C virus-related chronic liver infection 226
Squamous cell carcinoma antigen-1 (SERPINB3) polymorphism in chronic liver disease 225
Mood, cognition and EEG changes during interferon alpha (alpha-IFN) treatment for chronic hepatitis C. 221
Role of transient elastography to stage fontan-associated liver disease (Fald) in adults with single ventricle congenital heart disease correction 221
Performance and utility of transient elastography and noninvasive markers of liver fibrosis in primary biliary cirrhosis. 220
SERPINB3 expression on B-cell surface in autoimmune diseases and hepatitis C virus-related chronic liver infection 219
Selection and validation of miR-1280 as a suitable endogenous normalizer for qRT-PCR Analysis of serum microRNA expression in Hepatocellular Carcinoma 219
Profiles of HCV core protein and viremia in chronic hepatitis C: Possible protective role of core antigen in liver damage 203
HEART RATE VARIABILITY PARALLELS CHANGES IN PSYCHIATRIC SCALES IN INTERFERON-TREATED PATIENTS WITH CHRONIC HEPATITIS 202
Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C 201
Hepatitis C Virus Reinfection in Liver Transplant Patients: Evaluation of Liver Damage Progression with Echo-Color Doppler 199
Kinetic of virological response during PEG-IFNs in chronic hepatitis C. 196
HEPATITIS C VIRUS SEROTYPES AND LIVER PATHOLOGY 192
METABOLIC SYNDROME INDUCES A MORE RAPID PROGRESSION OF FIBROSIS IN PRIMARY BILIARY CIRRHOSIS IN EARLY STAGE 192
Hepatitis C virus reinfection in liver transplant patients: evaluation of liver damage progression with echo-color doppler. 190
Heart rate variability parallels changes in psychiatric scales in interferon-treated patients with chronic hepatitis. 189
PERFORMANCE OF TRANSIENT ELASTOGRAPHY AND NON INVASIVE MARKERS OF LIVER FIBROSIS IN PRIMARY BILIARY CIRRHOSIS 189
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 184
Monitoring SCCA-IgM complexes in serum predicts liver disease progression in patients with chronic hepatitis 184
Deregulation of Squamous Cell Carcinoma Antigen (SCCA) expression in B lymphocytes in patients with chronic hepatitis C 183
THE EFFECT OF INTERFERON ALFA AND RIBAVIRIN COMBINATION THERAPY IN NAIVE PATIENTS WITH CHRONIC HEPATITIS C 181
PERFORMANCE OF TRANSIENT ELASTOGRAPHY AND NON INVASIVE MARKERS OF LIVER FIBROSIS IN PRIMARY BILIARY CIRRHOSIS 179
Squamous cell carcinoma antigen (SCCA) expression and CD27+ memory B lymphocytes in patients with chronic hepatitis C 178
Serum miRNA are promising biomarkers for the detection of early hepatocellular carcinoma after treatment with direct-acting antivirals 178
Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. 175
HFE, TGF-BETA1 AND SQUAMOUS CELL CARCNOMA ANTIGEN-1 POLYMORPHISMS AND LIVER DISEASE STAGE IN CHRONIC HCV INFECTION 175
Liver Angiopoietin-2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct-Acting Antivirals 173
Human leucocyte interferon-alpha in the treatment of chronic hepatitis C 172
Alterazioni neurovascolari nell’epatite cronica C: uno studio caso-controllo 172
Relapse after direct-acting antivirals (DAAs) in cirrhotic patients with hepatitis C is highly related to development of liver cancer 171
Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C. 170
Prevalence and characteristics of peripheral neuropathy in hepatitis C virus population 167
KINETIC OF VIROLOGICAL RESPONSE DURING PEG-IFNS IN CHRONIC HEPATITIS C. 165
COMPARISON OF THRICE WEEKLY VS DAILY HUMAN LEUCOCYTE INTERFERON-ALPHA THERAPY FOR CHRONIC HEPATITIS C. TVVH STUDY GROUP. 164
Therapy of hepatitis C: re-treatment with alpha interferon. 163
Control and Operational Management of a Fuel-Cell Supply System for Electric Bicycle 160
Monitoring SCCA-IgM complex predicts liver disease progression in patients with chronic hepatitis and cirrhosis 160
POLIMORFISMO DI SCCA (SQUAMOUS CELL CARCINOMA ANTIGEN) E PROGRESSIONE DELLA MALATTIA EPATICA NELL’INFEZIOE HCV 159
Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort 159
SCCA EXPRESSION IN PBMCs IN PATIENTS WITH CHRONIC HEPATITIS C 156
Comparison of thrice weekly vs daily human leucocyte interferon-alpha therapy for chronic hepatitis C. TVVH Study Group. 151
ESPRESSIONE DELLA SERPINA SCCA IN CELLULE MONONUCLEATE DI SANGUE PERIFERICO IN PAZIENTI CO INFEZIONE CRONICA DA HCV 148
Preventing interferon-induced depression in a sample of 44 chronic hepatitis C patients with risk factor for depression 146
Validation of a new sonographic parameter (liver/kidney ratio of greys intensity of digital images) for diagnosis and quantification of liver steatosis 146
Changes in serum tryptophan during antiviral therapy with recombinant alfa-interferon in chronic hepatitis C 145
CLINICAL SIGNIFICANCE OF SERUM AND LIVER TISSUE SCCA IN CHRONIC HEPATITIS 145
Espressione della serpina SCCA in cellule mononucleate di sangue periferico in pazienti con infezione cronica da HCV 142
HEART RATE VARIABILITY PARALLELS CHANGES IN PSYCHIATRIC SCALES IN INTERFERON-TREATED PATIENTS WITH CHRONIC HEPATITIS. 142
DOWNREGULATION OF SURFACE SQUAMOUS CELL CARCINOMA ANTIGEN EXPRESSION AND CD27+ MOLECULE ON B LYMPHOCYTES IN PATIENTS WITH CHRONIC HEPATITIS C 141
The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C 140
CHRONIC HEPATITIS C WITHOUT ANTIBODY TO C-100 135
Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of data from European Centers. 134
Standard therapy for chronic HCV infection 134
Monitoring SCCA-IgM complex predicts hcc development in cirrhotic patients 132
Comparison of thrice weekly vs daily human leucocyte interferon-alfa therapy for chronic hepatitis C. 132
RESPONSE TO RIBAVIRIN, TO INTERFERON AND TO A COMBINATION OF BOTH IN PATIENTS WITH CHRONIC HEPATITIS C AND ITS RELATION TO HCV GENOTYPES 131
Terapia con Peg-interferone e ribavirina nell'epatite cronica C: costo-efficacia e farmacoutilizzazione nella comune pratica clinica 130
Epidemiological and clinical profile of HCV Chronic carriers in the area of northern Italy 128
NEUROCYTOKYNES CHANGES INDUCING PEG-INTERFERON-ALPHA DEPRESSION: A RATIONAL APPROACH TO INCREASE ADHERENCE OF THERAPY IN CHRONIC HEPATITIS C 127
Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group 126
Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features. 126
L'osservatorio epidemiologico e clinico sulle epatopatie croniche: uno strumento di politica sanitaria. 125
ESPRESSIONE DI SCCA (SQUAMOUS CELL CARCINOMA ANTIGEN) E CELLULE B DELLA MEMORIA IN CORSO DI INFEZIONE DA VIRUS DELL’EPATITE C 125
Non invasive diagnosis of liver fibrosis progression by a clinical and us-doppler predictive model during chronic HCV infection 124
Aspetti farmacoeconomici della terapia antivirale nell'epatite cronica C 121
HEPATITIS C: DIAGNOSIS AND THERAPY 119
PREDICTORS OF SVR IN PATIENTS WITH NAIVE CHRONIC HCV TREATED WITH PEG-IFN ALFA-2B VS. ALFA-2A + RIBAVIRIN: A HIERARCHICAL LINEAR REGRESSION ANALYSIS OF RETROSPECTIVE DATA FROM 6 CLINIC SITES. 118
Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C. 118
impact of direct acting antivirals (Daa) on neurologic disorders in chronic hepatitis C 118
LE STRATEGIE TERAPEUTICHE NELL’INFEZIONE CRONICA DA VIRUS DELL’EPATITE C 116
TIMING AND DOSE EFFECT OF ALPHA-INTERFERON ON EARLY VIRAL KINETICS IN CHRONIC HEPATITIS C 115
RESPONSE TO RIBAVIRIN, TO INTERFERON AND TO A COMBINATION OF BOTH IN PATIENTS WITH CHRONIC HEPATITIS C AND ITS RELATION TO HCV GENOTYPES 114
RETREATMENT OF CHRONIC HEPATITIS C (CHC) WITH SEQUENTIAL INTERFERON RIBAVIRIN COMBINATION (IFN-RIBA) THERAPY 113
THE EFFECT OF RE-TREATMENT WITH INTERFERON ALONE OR INTERFERN PLUS RIBAVIRIN ON HCV QUASISPECIES DIVERSIFICATION IN NONRESPONDER PATIENTS WITH CHRONIC HEPATITIS C 111
Novel pharmacogenetic test for management of antiviral therapy in patients with chronic hepatitis C 111
THE LONG-TERM RESPONSE (LTR) TO INTERFERON-ALPHA (IFN-2a) IN CHRONIC HEPATITIS C IS INFLUENCED BY DOSE AND DURATION OF TREATMENT AND BY THE HCV SEROTYPE 110
Non-invasive diagnosis of liver fibrosis progression by a clinical and US-Doppler predictive model during chronic HCV infection 110
DIFFERENT RATES OF HCV QUASISPECIES DIVERSIFICATION IN ASYMPTOMATIC CARRIERS AND IN PATIENTS WITH CHRONIC HEPATITIS 108
Neurophysiological bases of IFN toxicity in the treatment of viral hepatitis: Psychiatric, cognitive changes and long-term electrophysiological correlates. 108
ESTIMATE OF FIBROSIS PROGRESSION DURING CHRONIC HEPATITIS C (CHC) IN NORTH-EAST ITALY 102
The effect of interferon alpha and ribavirin combination therapy in naive patients with chronic hepatitis C. 100
Studio epidemiologico e prospettico delle epatopatie croniche: un progetto pilota nelle province di Padova e Venezia 98
Evidence for sequence selection within the non-structural 5A gene of hepatitis C virus type 1b during unsuccessful treatment with interferon-alfa. 97
EVIDENCE THAT DOSE AND DURATION OF INTERFERON ALPHA (IFNa) THERAPY AFFECT LONG-TERM RESPONSE IN CHRONIC HEPATITIS C 97
Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C. The TVVH Study Group. 97
PEGYLATED ALPHA INTERFERONS (PEG-IFNs) PERIPHERAL NEUROTOXICITY: PROSPECTIVE STUDY IN CHRONIC HEPATITIS C. 95
INTERFERON THERAPY FOR CHRONIC VIRAL HEPATITIS : STATUS REPORT 95
SIGNIFICANCE OF HEPATITIS C VIRAEMIA IN ASYMPTOMATIC ANTI-HCV CARRIERS 94
EFFICACIA DI DIFFERENTI TIPI DI DOSAGGI DI ALPHA-INTERFERONE IN SOGGETTI CON EPATITE CRONICA DI TIPO C 92
Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. 91
LATE REACTIVATION OF CHRONIC HEPATITIS C AFTER SUSTAINED BIOCHEMICAL RESPONSE TO INTERFERON THERAPY 87
PROBABILITA’ DI REATTIVAZIONE DELL’EPATITE C DOPO TERAPIA CON ALFA-INTERFERONE IN SOGGETTI CON PERSISTENTE RISPOSTA BIOUMORALE 87
SIGNIFICANCE OF ANTIBODIES TO DIFFERENT HCV ANTIGENS IN ACUTE AND CHRONIC HEPATITIS 86
IS SUSTAINED RESPONSE TO ?-INTERFERON IN CHRONIC HEPATITIS C REALLY MANTAINED AT LONG-TERM FOLLOW-UP ? 86
Totale 15.606
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.741
article - articoli 35.453
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 926
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.514
Totale 85.634
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.007 0 169 89 93 35 70 42 94 58 30 117 210
2022/20231.005 225 79 20 85 183 123 19 63 114 25 60 9
2023/2024421 13 51 45 33 37 53 27 13 12 12 60 65
2024/20252.115 7 118 95 67 278 46 61 159 192 106 428 558
2025/20268.195 368 655 1.178 1.205 735 298 1.148 795 851 501 314 147
2026/2027327 270 57 0 0 0 0 0 0 0 0 0 0
Totale 16.300